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Clinical and genetical aspects of autosomal dominantly
inherited  osteogenesis imperfecta tarda
ABSTRACT                        Osteogenesis imperfecta (OI) tarda dominant type is caused by mutations in the
type I collagen genes, COL1A1 and COL1A2. The essence of our haplotype analysis of
osteogenesis imperfecta (OI)  was to get information about the value of 8 short tandem repeat
(STR) markers for the segregation of COL1A1 and COL1A2 genes on the 12 OI pedigrees and
to delimit the place of mutation to one locus. The molecular genetic analysis supported the
linkage to COL1A1 gene in 6 families, and in 4 families with type I B, and in one family with
type III B the linkage to COL1A2 gene was supported. One patient had type IV A, where linkage
to COL1A1 gene had been excluded, and haplotype analysis for COL1A2 was non conclusive
in six families. As both genes consist of more than 50 exons, the haplotype analysis is very
important before direct mutation screening. To achieve the maximum theoretical LOD scores
for the haplotype analysis, more STR markers are needed as in many cases our markers were
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Osteogenesis imperfecta (OI) is characterised by brittle
bones, pathologial fractures, blue sclera, dentinogenesis
imperfecta (with or without) and caused by mutations in the
type I collagen genes, COL1A1 and COL1A2.
All types of osteogenesis imperfecta are caused by
structural or quantitative defects in type I collagen, the
primary component of the extracellular matrix of bone and
skin. In about 10% the of clinically indistinguishable cases,
no biochemical defect of collagen protein can be demonstrat-
ed. It is not clear whether these cases represent limitations
in biochemical detection or genetic heterogeneity of the
disorder.
OI is an autosomal dominant disorder that occurs in all
racial and ethnic groups. The incidence of detectable OI in
infancy is about 1 in 20,000. There is a similar incidence of
the mild form, type I OI.
Pathology: The collagen structural mutations cause OI
bone to be globally abnormal. The bone matrix contains
abnormal type I collagen and relatively increased levels of
types III and V collagen. In addition, several non collagenous
proteins of bone matrix are found in reduced amounts. The
hydroxyapatite crystals deposited on this matrix are poorly
aligned with the long axis of fibres.
Pathogenesis: Type I collagen is a heterotrimer, composed
of two α-1 (I)-chains and one α2(I)–chain. The chains are
synthesized as pro collagen molecules with short globular
extensions on both ends of the central helical domain. The
helical domain is composed of uninterrupted repeats of the
sequence Gly-X-Y, where Gly is glycine, X is mostly proline,
and Y is mostly hydroxyproline. The presence of glycine at
every third residue is cruical to helix formation because its
small side chain can be accomodated in the spatial constraints
of the interior of the helical trimer. Concomitant with helix
assembly and formation, the chains are glycosylated at lysine
residues.
The collagen structural defects are of two types: 85% are
point mutations causing substitutions of glycine residues by
other amino acids, 12% are single exon splicing defects.The
clinically mild type I OI has a quantitative defect with
mutations that cause one a1(I) allele to be functionally void.
These patients make a reduced amount of normal collagen.
The relationship between genotype and phenotype remains
elusive for the structural mutations. Lethal and nonlethal
mutations occur with about equal frequency on both chains.
For α2(I) mutations, lethal and nonlethal mutations occur in
alternating regions along the chain. For mutations on the
α1(I)-chain, no model adequately predicts the phenotype. A
minority of OI cases with apparent recessive inheritance are
due to parental mosaicism and are also dominant.
Pace et al. (2002), identified a mutation in the carboxyl-
terminal propeptide coding region of one COL1A1 allele in
an infant who died with an OI phenotype that differed from
the usual lethal form and had regions of increased bone
density.
Linkage studies were performed for genetic markers from
candidate intervals known to contain genes responsible for
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Table 1. STR markers for the haplotype analysis of COL1A1 and
COL1A2 loci
D17S788F 5' CTA GGC AGC CAC TAC CAA AT
D17S788R 5' CAG CAT CTT TGC TAT AAG CAT C
D17S790F 5' AGG AAA AAT GAG TGG ACC AT
D17S790R 5' AGC TGG GTT ATT GTT TTT CC
D17S943F 5' GGT GGA GGG AGT AGA AAG AA
D17S943R 5' TAT GGC TGT CTC ATT CCA AC
D17S1795F 5' AGT GCC AGA GATATA CCG TG
D17S1795R 5' GTC TGC AAG GCA AGT TGT C
D7S657F 5' TCA ATC ACC ACT TAC ATG CA
D7S657R 5' AGA GAA GTG GTG TCA CTT GG
D7S527F 5' TGT TTC TTC AAG GTA GTC
D7S527R 5' TAA CAG AGG CAT GAA AAC CA
D7S2482F 5' TTA ATC CCA CAG GAA TGA ATG
D7S2482R 5' TGG CTC TAG AAT TCT GAA TGG
D7S1820F 5' TGA ATG ACT TTG GTG AGT ATG C
D7S1820R 5' ACC TCA AGC AGA ACA CTT GC
dentinogenesis imperfecta (DGI) on chromosomes 4q, 7q,
and 17q. Conclusive evidence for linkage of DGI was
obtained for genetic markers on chromosome 17q21-q22
(DLX-3, Z(max) = 5.34, theta = 0.00; Pallos et al. 2001). This
was the first report of joint pain associated with a COL1A1
mutation and DGI. The mild skeletal features and reduced
penetrance of the non-dental findings illustrate the impor-
tance of genetic evaluations for families with a history of
DGI.
McKenna et al. (2002) determined whether milder ab-
normalities in COL1A1 expression might account for the
development of otosclerosis in the 7 clinical cases that did
not reveal evidence of zero expression by the gel technique.
Of the same 2 cases of otosclerosis that demonstrated
evidence of zero expression by gel electrophoresis, both were
found to have significant differences in COL1A1 mRNA
expression by the Taqman analysis. The remaining 7 cases
revealed equal expression of the two COL1A1 alleles similar
to that seen in controls. These results suggest, that mutations
in COL1A1 which are similar to those in type I osteogenesis
imperfecta may account for a small percentage of cases of
otosclerosis, and that the majority of cases of clinical
otosclerosis are related to other genetic abnormalities that
have yet to be identified.
In summary, there are two known loci (COL1A: at
chromosome 17, 17q21.31-q22; COL1A2: at chromosome 7,
7q22.1) of osteogenesis imperfecta type I; 70-80% of these
patients carry mutations in one or both of these genes.
The aim of our study was to analyse the segregation of
the autosomal dominant osteogenesis imperfecta type I in
some Hungarian families and to evaluate the usefulness of
short tandem repeat markers (STR) for the linkage analyses
of certain loci of collagen gene.
Materials and Methods
In our retrospective study we investigated 18 families with
autosomal dominant inherited osteogenesis imperfecta tarda
(OIT) type I, III and IV from the Pediatric Department
Szeged and 12 families from the Semmelweis University
Department of Orthopedics, Budapest. Diagnostic criteria for
OIT were pathological bone fractures, blue sclera, dentino-
genesis imperfecta, scoliosis (w/wo). Type II (lethal) did not
occur.
We chose 4-4 short tandem repeat (STR) markers (Table
1) for the haplotype analysis of the two loci (COL1A1 and
COL1A2). The markers were D17S788, D17S790, D17S943,
D17S1795 for COL1A1, and D7S657, D7S527, D7S2482,
D7S1820 for COL1A2. The touch down PCR amplifications
were carried out by the following program: initial denatur-
ation at 94°C for 5 min followed by 10 cycles denaturation
at 94°C for 30 sec, annealing at 61°C for 30 sec (-0.5°C per
cycle) and extension at 72°C for 30 sec continued for 25
cycles of denaturation at 94°C for 30 sec, annealing at 57°C
for 30 sec and extension at 72°C for 30 sec followed by a
final extension at 72°C for 10 min for all markers except for
D17S943 where we had the same program but the annealing
temperatures were 5°C higher, respectively. The PCR prod-
ucts were run on 8% polyacrylamide (PA) gel and visualized
by ethidium bromide with an AlphaImager, AlphaEase 5.5
gel documentation system (Fig. 1).
Results
Twelve OIT families, 3-7 family members per family, in-
cluding 2-4 members affected by autosomal dominant
inheritance (AD) per family, had been genotyped by STR
markers for the COL1A1 and COL1A2 loci. The clinical and
genetical data of our OIT patients have been summarized in
Table 2. Eight out of twelve OIT families had type I, among
them 5 families had type I B, the molecular genetic analysis
supported the linkage to COL1A1 gene in 6 families, and in
4 families with type I B and in one family with type III. B
the linkage to COL1A2 gene was supported.
One patient had type IV A, where linkage to COL1A1
gene had been excluded, and haplotype analysis for COL1A2
was non conclusive. The K. brother’s had type IV B with
COL1A1 mutation.
Figure 1. Haplotype analysis of the family of M. Sz. The amplified
PCR products were run on 8% PA gel. We could exclude the COL1A1
locus with several markers as affected children inherited different
alleles from the affected mother. The STR markers of COL1A2 locus






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































One female patient had type III B with intrauterine
fractures and very severe short state (115 cm) and clinical
prognosis with multiplex extra uterine fractures. She had
been operated several times, and developed kyphoscoliosis.
She completed her secondary school with excellent marks,
and she is unable to walk. The affection of COL1A2 has been
supported and COL1A1 gene has been excluded.
Thus the molecular genetic data linkage to COL1A1 gene
was confirmed in 6 families,  and in 3 families this gene was
excluded. The linkage to COL1A2 was confirmed in 3
families-with type I B (n=2) and type III (n=1)-and in one
family the locus was excluded.
The STR markers for COL1A2 gene were non informa-
tive in 6 families.
Discussion
Because of the low number of patients in several of our
families, we were able to carry out the haplotype analysis in
12 families only.
Tsipouras et al. (1984) performed linkage analysis of the
four RFLPs of the COL1A2 in families with mild forms of
osteogenesis imperfecta and in a family with Marfans
syndrome. In 2 of the OI positive families lod scores were
found. In three other families the osteogenesis imperfecta
phenotype segregated independently of the polymorphisms.
Accumulative lod score from these 3 families was -4.3 at
recombination fraction 0.05, and close linkage is excluded.
The data from these 5 families with OI support the hypothesis
that the mild dominant osteogenesis imperfecta is heter-
ogeneous at the gene level. Skyes et al. (1986) found a
polymorphism in the COL1A1 gene, and they have used this
together with the polymorphisms at the COL1A2 gene in
linkage studies in 11 families with dominant OI. In each
family the OI gene was inherited with one or the other
collagen locus. OI phenotype IV seemed to segregate with
the COL1A2 gene, which is in agreement with the COL1A2
gene in four families and with COL1A2 in one family
(Borresen 1986).
Comparison of phenotypic features with the concordant
collagen locus showed that in four pedigrees with OI Sillence
type I segregated with COL1A1, while two pedigrees with
OI Sillence type I and OI type IV segregated with COL1A2.
In the five of our OI type I families the linkage to
COL1A1 gene have been supported by the haplotype analy-
sis. COL1A1 locus dimorphisms A/MspI, B/RsaI and F/
MnlI, showed PIC values of 0.327, 0.191 and 0.366, respec-
tively, giving a combined PIC of 0.656 at the locus, while
COL1A2 locus dimorphisms C/EcoRI, D/MspI and E/RsaI
RFLPs had PIC values of 0.357, 0.168 and 0.331, respective-
ly, giving a combined PIC of 0.655 at the locus ( Benuslene
and Kucinskas 2000).
The cell surface expression and functional properties of
TGF-β receptors I, II and III on osteoblasts were compared
to healthy controls. The human osteoblastic cells from
investigated patients with OI all have an elevated number of
cell surface receptors for TGF-β, without any evidence for
a transcriptional regulation of TGF-β receptor II. On the
functional level, there is some evidence for an impaired
adaptive behavior of receptor presentation, whereas receptor
affinity is unchanged (Gebken et al. 2000).
Apart from the affected bone density, the other main
manifestation of OI is the dentinogenesis imperfecta and the
otosclerosis.
Recurrent mutations in the COL1A2 gene (1121 G>T,
Gly 238 cys) in patients with osteogenesis imperfecta type
III were reported by Trummer et al. (2001). A new recurrent
point mutation in the COL1A2 gene was found in a patient
with type III OI. A G-to-T transversion in nucleotide position
1121 leads to an amino acid substitution Gly238Cys. This
was the first report on the most N-terminal cysteine sub-
stitution in COL1A2 reported to date. Until now, at this
position, only serine substitutions were observed five times
in unrelated patients showing a highly variable expression of
OI. Our patient (Ms. K. É.) with type III is a candidate for
COL1A2 gene mutation because her STR data were support-
ive for COL1A2 gene affection.
Prenatal diagnosis of a novel COL1A1 mutation in
osteogenesis imperfecta type I carried through full term
pregnancy was published by Ries et al. (2000). The father has
OI type I, with a novel mutation in the COL1A1 gene: a C
to T change at position c3076 (c.3076C—>T) leading to a
change of arginine at codon 848 to a stop codon (R848X).
Prenatal diagnosis by chorionic villous sampling (CVS) was
performed during the fourth pregnancy, and revealed that the
fetus is a carrier of the same COL1A1 mutation. The parents
elected to carry the pregnancy to term, and a male child with
mild OI was born.
The only serious attempts to show linkage in OI have
shown that the disease is linked to type 1 collagen genes in
all studied families in which it segregrates as a clear men-
delian dominant trait. For prenatal diagnosis the probability
that a new family is linked can be taken as greater than 0.95.
Some phenotype correlations, notably between the OI type
IV phenotype and linkage to COL1A2 and between presenile
hearing loss in OI type I and linkage to COL1A1, can be used
to improve risk estimates substantially in families where
there are no segregation data to distinguish whether COL1A1
or COL1A2 is the mutant locus (Sykes 1993).
The segregation of COL1A1 and COL1A2, the two genes
which encode the chains of type I collagen, was analyzed in
38 dominant OI pedigrees by using polymorphic markers
within or close to the genes. This was done in order to
estimate the consistency of linkage of OI genes to these two
loci. None of the 38 pedigrees showed evidence of re-
combination between the OI gene and both collagen loci,
suggesting that the frequency of unlinked loci in the pop-
ulation must be low. From these results, approximate 95%
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confidence limits for the proportion of families linked to the
type I collagen genes can be set between .91 and 1.00. This
is high enough to base prenatal diagnosis of dominantly
inherited OI on linkage to these genes even in families which
are too small for the linkage to be independently confirmed
to high levels of significance. When phenotypic features were
compared with the concordant collagen locus, all eight
pedigrees with Sillence OI type IV segregated with COL1A2.
On the other hand, Sillence OI type I segregated with both
COL1A1 (17 pedigrees) and COL1A2 (7 pedigrees). The
concordant locus was uncertain in the remaining six OI type
I pedigrees. Of several other features, the presence or absence
of presenile hearing loss was the best predictor of the mutant
locus in OI type I families, with 13 of the 17 COL1A1
segregants and none of the 7 COL1A2 segregants showing
this feature (Sykes et al. 1990).
The essence of our haplotype analysis of OI was to get
information about the value of 8 STR markers for the
segregation on the pedigrees and to delimit the place of
mutation to one locus. As both genes consist of more than 50
exons the haplotype analysis is very important before direct
mutation screening. From our study we can conclude that the
analysis of AD OI families is problematic as in most cases
the number of affected people and informative members in
the families are few. To achieve the maximum theoretical
LOD scores for the haplotype analysis more STR markers are
needed as in many cases our markers were non informative.
However by the data of HGP there are limited numbers of
available STR markers with high allele frequencies in 3-4 cM
proximity of COL1A1 and COL1A2 loci.
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